6 December 2017 in The EMBO Journal
Parkinson's disease predisposing LRRK2 kinase phosphorylates a group of Rab GTPase proteins including Rab29, within the effector‐binding switch II motif. Previous work indicated that Rab29, located within the PARK16 locus mutated in Parkinson's patients, operates in a common pathway with LRRK2. Here, we show that Rab29 recruits LRRK2 to the trans ‐Golgi network and greatly stimulates its kinase activity. Pathogenic LRRK2 R1441G/C and Y1699C mutants that promote GTP binding are more readily recruited to the Golgi and activated by Rab29 than wild‐type LRRK2. We identify conserved residues within the LRRK2 ankyrin domain that are required for Rab29‐mediated Golgi recruitment and kinase activation. Consistent with these findings, knockout of Rab29 in A549 cells reduces endogenous LRRK2‐mediated phosphorylation of Rab10. We show that mutations that prevent LRRK2 from interacting with either Rab29 or GTP strikingly inhibit phosphorylation of a cluster of highly studied biomarker phosphorylation sites (Ser910, Ser935, Ser955 and Ser973). Our data reveal that Rab29 is a master regulator of LRRK2, controlling its activation, localization, and potentially biomarker phosphorylation.
17 October 2019 in Journal of Cell Biology
LRRK2 kinase mutations cause familial Parkinson’s disease and increased phosphorylation of a subset of Rab GTPases. Rab29 recruits LRRK2 to the trans-Golgi and activates it there, yet some of LRRK2’s major Rab substrates are not on the Golgi. We sought to characterize the cell biology of LRRK2 activation. Unlike other Rab family members, we show that Rab29 binds nucleotide weakly, is poorly prenylated, and is not bound to GDI in the cytosol; nevertheless, Rab29 only activates LRRK2 when it is membrane bound and GTP bound. Mitochondrially anchored, GTP-bound Rab29 is both a LRRK2 substrate and activator, and it drives accumulation of active LRRK2 and phosphorylated Rab10 on mitochondria. Importantly, mitochondrially anchored LRRK2 is much less capable of phosphorylating plasma membrane–anchored Rab10 than soluble LRRK2. These data support a model in which LRRK2 associates with and dissociates from distinct membrane compartments to phosphorylate Rab substrates; if anchored, LRRK2 can modify misdelivered Rab substrates that then become trapped there because GDI cannot retrieve them.
15 June 2015 in Journal of the American Chemical Society
1 May 2026 in Molecular Therapy Advances
Incorporation of the 5′ cap into RNA is a critical quality attribute that requires accurate assessment for therapeutic application. Existing analytical approaches often rely on transcript-specific probes or sequence-dependent workflows, which limit throughput and platform-level applicability. Here, we describe a quantitative, transcript-independent LC-MS/MS assay for RNA cap incorporation designed to support RNA therapeutic process development and quality control, using CleanCap-AG as a representative co-transcriptional capping chemistry. The workflow combines nuclease P1 digestion with external calibration using authentic cap analog standards, enabling quantification of capped (CC-A) and uncapped (ATP) 5′ species while correcting for residual unincorporated reagents through paired digested and undigested analyses. The assay supports a 0.01–20 pmol calibration range using commercially available standards and a 10 min LC-MS/MS acquisition, facilitating high analytical throughput. Analytical characterization demonstrated excellent linearity (r2 > 0.995), accuracy (84%–102% recovery), and precision consistent with accepted bioanalytical criteria (RSD <15% at 1 and 10 pmol). Application to multiple RNA transcripts confirmed efficient digestion and accurate cap quantification independent of sequence context. This method provides a rigorously characterized, sequence-agnostic analytical platform for RNA cap analysis compatible with chemical and potentially enzymatic capping strategies, enabling scalable process development, lot comparability assessment, and manufacturing quality control.